rubitecan has been researched along with Experimental Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeJesus, A; Early, J; Giovanella, BC; Mendoza, J; Pantazis, P; Shaw, M | 1 |
| Early, JA; Giovanella, BC; Kozielski, AJ; Mendoza, JT; Natelson, EA; Pantazis, P | 1 |
2 other study(ies) available for rubitecan and Experimental Leukemia
| Article | Year |
|---|---|
Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs.
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia, Experimental; Microscopy; Tumor Cells, Cultured | 1994 |
9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Death; DNA, Neoplasm; Growth Inhibitors; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myeloid; Mice; Mice, Nude; Neoplasm Transplantation; Tumor Cells, Cultured | 1993 |